Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8268e39ce70ff2ad19742e2a21d5a90c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14141 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-79 |
filingDate |
2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_853ec207ff13d2a07a005bd78d2564a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3397a4867db425c7098d678f449ba45b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20cbb312af6b54555c5ca3474651c0ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6a182f93aeabe5d7858559953fcea10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_166d900ccc3fa7dbad0a82948f804572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30ab381b51176b28ae538a9031b6be71 |
publicationDate |
2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-3082370-A1 |
titleOfInvention |
Targeted crispr delivery platforms |
abstract |
The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the Neisseria meningitidis Cas9 system that provides a hvperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA. sequences that permit a complete sgRNA-Nme1Cas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 oithologs have been identified that target protospacer adjacent motif sequences limited to between one - four required nucleotides. |
priorityDate |
2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |